Description: The investment seeks investment results that correspond (before fees and expenses) generally to the performance of its underlying index, the Poliwogg Medical Breakthroughs IndexSM. The fund employs a "passive management" - or indexing - investment approach designed to track the performance of the underlying index. It will normally invest at least 80% of its net assets in securities that comprise the underlying index. The underlying index is comprised of small- and mid-cap stocks of biotechnology and pharmaceutical companies that have one or more drugs in either Phase II or Phase III U.S. Food and Drug Administration clinical trials. It is non-diversified.
Exchange: NYSE ARCA
Country: US
Currency: US Dollar ($)
Category: Health
| Asset Allocation | |||
|---|---|---|---|
| Asset Class | Long % | Short % | Net Assets |
| Stock US | 83.49 | 0.00 | 83.49 |
| Stock non-US | 16.49 | 0.00 | 16.49 |
| Cash | 0.01 | 0.00 | 0.01 |
| Sector Weights | ||
|---|---|---|
| Sector | Equity % | Relative to Category |
| Healthcare | 100.00 | 99.57 |
| World Regions | ||
|---|---|---|
| Region | Equity % | Relative to Category |
| North America | 86.21 | 92.60 |
| United Kingdom | 6.85 | 1.65 |
| Europe Developed | 3.93 | 4.28 |
| Asia Emerging | 3.01 | 0.82 |
| Japan | 0.00 | 0.54 |
| Australasia | 0.00 | 0.11 |
| Africa/Middle East | 0.00 | 0.02 |